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Abstract 
Purpose: lung cancer is the leading cause of cancer-related death. Among the new 
modalities to treat cancer, internal radiotherapy seems to be very promising. However, 
the achievable dose-rate is two orders of magnitude lower than the one used in 
conventional external radiotherapy, and data has to be collected to evaluate the cell 
response to highlight the potential effectiveness of low-dose-rate beta particles 
irradiation. This work investigates the phosphorus beta irradiation (
32
P) dose response on 
the clonogenicity of human A549 non-small cell lung adenocarcinoma cells and 
compares it to high-dose-rate X-irradiations results. 
Materials and methods: cell survival was evaluated by a colony forming assay 8 days 
after low-dose-rate 
32
P beta irradiations (0.8 Gy/h) and high-dose-rate X-ray irradiations 
(0.855 Gy/min).  
Results: survival curves were obtained for both types of irradiations, and showed hyper-
radiosensitivity at very low doses. Radiosensitivity parameters were obtained by using 
the linear-quadratic and induced-repair models.  
Conclusions: Comparison with high-dose-rate X-rays shows a similar surviving fraction, 
confirming the effectiveness of beta particles for tumor sterilization.  
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Introduction 
Lung cancer is the leading cause of cancer-related death. Besides traditional treatments, 
new modalities are under investigation; internal radiotherapy, like radio-immunotherapy 
(RIT), is a promising example. RIT is a biologically targeted radio-pharmaceutical 
treatment in which a radioactive isotope is chemically bound to a target-specific 
monoclonal antibody or antibody fragments with a high degree of specificity for one 
particular tumor associated antigen (Pohlman et al. 2006). RIT requires dealing with three 
interdependent factors: the tumor targeted by the treatment, the antibody and the 
radionuclide. Howell et al. (Howell et al. 1994) and Rao et al. (Rao & Howell 1993) have 
shown that one of the most promising radioisotope for RIT is 
32
P owing to its half life 
(14.3 days) and the tissue penetration of its beta radiation (8 mm maximum). Initially, 
this radioisotope was mainly used for the therapy of bone pain and metastases, in ovarian 
cancer and for myeloproliferative diseases (Pattillo et al. 1995; Berlin 2000; Pandit-
Taskar et al. 2004; Tennvall & Brans 2007). More recently, studies on the use of 
32
P as 
colloid or microsphere for solid tumors were performed; they showed not only an 
improvement in the patient’s quality of life, but also in their survival (Gao et al. 2008; 
Wang et al. 2008). However, 
32
P was not used in RIT due to the difficulty of the 
radiolabeling. Abraham and colleagues used decapeptides labeled with 
32
P for the 
colorectal cancer therapy (Abraham et al. 2007; Abraham et al. 2008) and showed that 
these molecules avidly bind to different adenocarcinoma cell lines with a permanent 
incorporation of radioisotopes into cellular proteins at a rate over 100 times greater than 
in cell lines derived from a variety of other cancers or from normal organs. The use of 
such small molecules allows for their elimination in the urine, as their molecular weight 
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is lower than the limit of the filtering kidney. Moreover, they can penetrate deeper into 
the tumor, which is, in combination with the long penetrating range of the 
32
P beta 
particles, highly attractive for the treatment of solid tumors. In parallel, investigations 
into the use of radioactive nanoparticles containing several radioactive atoms are 
currently underway to improve the therapeutic effectiveness of RIT and to enhance 
diagnostic sensitivity in medical imaging. Theoretical studies confirm the benefit of using 
radiolabeled beta emitter nanoparticles, such as 
90
Y2O3 or 
32
P2O3, to treat solid and poorly 
vascularized tumors by RIT (Bouchat et al. 2007; Nuttens et al. 2008). Nevertheless, the 
currently achievable dose-rate in RIT is one or two orders of magnitude lower than the 
one obtained by external X-ray radiotherapy.  
One major question still remains: is it possible to obtain adequate cell sterilization with 
beta radiation with a dose-rate that is one or two orders of magnitude lower than with 
traditional X-rays? The aim of this work is to try to answer this question by studying the 
clonogenic survival of human A549 adenocarcinoma non-small cell lung cells irradiated 
with beta radiation emitted by 
32
P (0.8 Gy/h) and to compare the results with data 
obtained with X-ray irradiation (0.855 Gy/min).  
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Materials and Methods 
Cell culture and irradiation 
A549 (ATCC-LGC Standards, Molsheim, France) cells were grown in MEM (Minimum 
Essential Medium) (Invitrogen, Merelbeke, Belgium) containing 10% fetal calf serum 
(FCS) (Invitrogen). Both beta and X-ray irradiations were performed 24 hours after 
plating.  
32
P irradiations were performed at 37°C with a Na2H
32
PO4 solution (PerkinElmer, 
Waltham, Massachusetts, USA) as 
32
P source in serum-free CO2-independent medium 
(Invitrogen) supplemented with 1 mM L-glutamine (Sigma, Bornem, Belgium). 
32
P is a 
pure beta-emitting radionuclide with a physical half-life of 14.3 days. The maximum and 
mean beta particle energies are, respectively, 1.75 and 0.695 MeV. The source was 
calibrated to have a specific activity of 12 mCi/ml at the irradiation day. The irradiation 
duration and the radioactive volume were adapted to reach respectively the required dose 
and dose-rate. After incubation, cells were washed twice with phosphate-buffered saline 
(PBS) (Invitrogen) and replaced in MEM + FCS. The cellular uptake of 
32
P radionuclide 
was evaluated using a scintillation counter (Beckman Coulter Inc., Fullerton, CA, USA) 
after cell solubilization in 250 µl NaOH and neutralization with 250 µl HCl. 
A549 cells were exposed to X-rays (RT250, Philips Medical Systems, Bruxelles, 
Belgium) at 0.855 Gy/min (51.3 Gy/h) in the same condition as for 
32
P.  
Dosimetry simulation 
The deposited dose was calculated by MCNPX (Monte Carlo N-Particle eXtended) 
simulations (Pelowitz 2005) (code version 2.5.0) according to the calculation method 
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proposed by Schaart et al. (Schaart et al. 2002) to assess the dose deposited by 
32
P in a 
solution of Na2H
32
PO4 on A549 cells. It treats a three dimensional configuration of 
materials in geometric cells bounded by first- and second-degree surfaces and fourth-
degree elliptical tori (Pelowitz 2005). Working with charged particles as electrons in very 
small geometric cells leads to some uncertainties that are inherent in the condensed 
history method. Indeed, Schaart et al. have shown that this leads to significant errors in 
the absorbed dose (Schaart et al. 2002). They proposed a new method, used here proper 
evaluation. The calculations were performed using the track length estimator tally F4, 
combined with a dose response function. The ITS (Integrated Tiger Series) energy 
indexing algorithm was used (Debug Information Card: DBCN 17j 1). The photon and 
electron energy cut-offs were set to 1 keV as particles with less energy can not pass 
through the culture medium and reach the biological cells to damage them. The geometry 
of the experiment was a culture well whose bottom was covered by A549 cells (one 
confluent monolayer). The plastic well was filled with a radioactive 
32
P aqueous solution. 
The cell chemical composition was taken from the National Institute of Standards and 
Technology data base (NIST). 
The cell thickness was experimentally measured by confocal microscopy after 
immunofluorescence staining. An average thickness of 3.2 µm  0.1 µm was obtained 
over more than 30 measurements. 
Knowing the cell thickness, it was possible to evaluate the dose delivered by using the 
Tally T value. The obtained values were 7.047 10
-2
 and 6.200 10
-1
 MeV/g/nps for 6-well 
and 24-well plates, respectively. This corresponds to the mean deposited energy (MeV) 
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for an incident particle (nps) per mass unit (g). This value can be converted to dose-rate 
( D ) in Gy/h using: 
TAkD ..  
where A is the source activity (mCi) that gives the number of emitted beta particles per 
unit time, and k is the unit conversion constant (equal to 21.34) to obtain the unit of dose-
rate (J/kg/h or Gy/h) from the multiplication of the tally by the activity (MeV/g/s). 
The T value is specific to the geometry used in these experiments. As the source activity 
is 12 mCi/ml, the amount of radioactive solution added to the medium has been adjusted 
to obtain a dose-rate of 0.8 Gy/h. The exposition time has been adapted to reach the total 
targeted dose.  
The cellular uptake of 
32
P into exposed cells after the irradiation was experimentally 
measured: it was less than 0.05 % for each dose. This result allowed us to neglect the 
residual activity incorporated into the cells and to consider the total dose equal to the one 
obtained by the simulations.  
 Colony-Forming Assay 
Two thousand A549 cells were seeded in 6-well plates. Control cells underwent exactly 
the same manipulations without the addition of the radioisotope for 
32
P or without X-ray 
irradiation. 8 days post-irradiation, the number of visible colonies (containing > 50 cells) 
was counted after staining cells with crystal violet. The surviving fraction was obtained 
by calculating the ratio of the colony number for the irradiated cells to the colony number 
for control cells.  
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Survival curve analysis 
The results obtained from the colony forming assays were analyzed with the Linear-
Quadratic (LQ) model and the Induced-Repair model (IndRep). The LQ model allows the 
determination of the two radiosensitivity parameters α and β:  
²)( DDeS    
where S is the surviving fraction and D is the deposited dose. The LQ model considers 
cell killing as the result of single or double hit events into DNA. In different studies, a 
deviation between experimental data and the LQ model was observed. This deviation is 
due to hyper-radiosensitivity (HRS) which has been reviewed in (Raaphorst & Boyden 
1999; Joiner et al. 2001; Leskov et al. 2003; Marples et al. 2004). To obtain a better 
approximation of the data at low doses, the Induced-Repair model has been suggested to 
match this HRS as well as the induced radioresistance observed by increasing doses until 
1 Gy.  
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The IndRep model is an adaptation of the LQ model to allow the α parameter to vary with 
the dose (Short & Joiner 1998). The model defines four parameters: αr and β obtained 
with the LQ model; αs and Dc characterizing the HRS. 
The surviving fractions were fitted using Origin 7.5 (OriginLab) using a chi-square 
minimization method.  
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Results 
Survival curves for 
32
P irradiation 
The irradiations were performed at 0.8 Gy/h for doses ranging from 0.125 to 10 Gy. This 
dose-rate is within the usual range used in RIT and can be considered as a low-dose-rate. 
Four independent irradiation experiments with at least 4 replicates each were performed 
(Figure 1A). The experimental data were fitted with both LQ and IndRep models. The 
LQ model gave parameters equal to 0.21 ± 0.02 Gy
-1
 and 0.019 ± 0.002 Gy
-2
 for α and β 
respectively. The ratio α/β is 11.0 ± 2.1 Gy. At low doses from 0.125 to 0.5 Gy, a 
deviation between experimental data and the LQ model was observed (inset of Figure 
1A). This deviation is due to HRS and is highlighted by linearization of the surviving 
fraction (Figure 1B). A better approximation of the data at low doses was obtained with 
the IndRep model (see fit in Figures 1A and 1B). The values obtained for αs and Dc are, 
respectively, 2.1 ± 1.2 Gy
-1
 and 0.27 ± 0.10 Gy. The ratio αs/αr  is equal to 10.4 ± 6.9, 
indicating that cells are about ten times more sensitive at very low doses than at higher 
doses.  
Survival curves for X-ray irradiation  
The surviving fraction of A549 cells after X-ray irradiation (0.855 Gy/min) is shown in 
Figure 2A. The experimental data were fitted with both LQ and IndRep models. The 
parameters obtained with LQ model are 0.14 ± 0.02 Gy
-1
 and 0.038 ± 0.003 Gy
-2
 for α 
and β respectively. At low doses from 0.125 to 0.5 Gy, a deviation between experimental 
data and the LQ model was observed (inset of Figure 2A). This deviation, highlighted by 
linearization (Figure 2B), is due to HRS and is comparable to the deviation observed for 
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beta particles. The data were fitted with the IndRep model giving a αs value of 1.8 ± 1.2 
Gy
-1
 and a Dc value equal to 0.22 ± 0.11 Gy. A comparison was made between the 
surviving fraction obtained with 
32
P and X-ray irradiations (Figure 3). We observed a 
nearly complete overlay between both curves, with the curve for X-ray irradiation being 
just slightly more shouldered. Although irradiations were performed with serum-free 
medium to avoid progression in the cell cycle, effects of irradiation time may occur, and 
if so, influence the surviving fraction. Table I presents the value obtained for the 
parameters from the two models for each type of irradiation. The surviving fraction at 2 
Gy and the mean inactivation dose ( D ) are also presented. Fertil et al. (Fertil & Malaise 
1985) have previously shown that the initial part of the surviving fraction curve, which is 
well characterized by r and D , was specific of the cell line. Following their 
classification, the results obtained with beta and X-rays radiation show that A549 cells 
belong to the group of cell lines derived from tumors exhibiting low radioresponsiveness.  
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Discussion 
This work compares the clonogenic survival of A549 cells after low-dose-rate beta 
irradiations to high-dose-rate X-rays irradiations. For the 
32
P exposures, a low-dose-rate 
of 0.8 Gy/h was chosen. This dose-rate is in the range of those actually used in 
radionuclide therapy in which beta particles are involved.  
The surviving fraction curve showed that 60% of the cells were still able to grow colonies 
at 2 Gy, this fraction decreased to less than 3 % at 10 Gy. For X-rays, 65% and less than 
1% of survival was observed for 2 Gy and 10 Gy respectively.  
For the two types of radiations, a deviation from the LQ model was observed at low 
doses. This low dose hypersensitivity was highlighted in many tumor cell lines and was 
called hyper-radiosensitivity (HRS) (Joiner et al. 2001). HRS is usually displayed for 
doses below 0.5 Gy. Several explanations have been proposed by Joiner et al. (Joiner et 
al. 2001). This phenomenon seems to precede the occurrence of a relative resistance to 
cell killing by radiation over the dose range of 0.5-1 Gy.  Enns et al. (Enns et al. 2004) 
have also evidenced a HRS for A549 cells but with gamma irradiation. They have shown 
that HRS is due to apoptotic death and happens during the first cell cycle post-irradiation. 
The surviving fraction curves obtained in this work are characteristics of sparsely 
ionizing radiation, such as X-rays or beta particles. Fertil & Malaisse have demonstrated 
the correlation between in vitro radiosensitivity and clinical radioresponsiveness (Fertil & 
Malaise 1985). Following their classification, a radiosensitivity parameter α around 0.20 
Gy
-1
 corresponds to cell lines derived from tumor exhibiting low radioresponsiveness.     
The surviving fraction results obtained with beta particles on A549 cells were compared 
to the ones obtained with X-ray irradiation: beta particles led to a similar decreasing 
 12 
survival, while the dose-rate was 65 times lower. The surviving fraction at 2 Gy (0.61) 
obtained for 
32
P was slightly smaller than the one obtained with X-rays (0.65). Our data 
are also comparable to those reported in the literature. Munshi et al. obtained a surviving 
fraction of 0.61  0.004 at 2 Gy with high-dose-rate gamma radiation from 137Cs (Munshi 
et al. 2006). Moreover, Bromley et al. obtained parameter of 0.2432 Gy
-1
 and 0.0257 Gy
-2
 
for  and  respectively for A549 cells irradiated using 6 MV X-rays produced by a 
linear accelerator (Bromley et al. 2009). These values are close to the ones obtained in 
this work (0.21 Gy
-1
 and 0.019 Gy
-2
).  
The little difference between the results obtained with beta radiation at low dose-rate and 
high dose-rate X-rays may be surprising, as it is generally thought that the radiation 
effects increase with the dose-rate. However, many studies have shown what was termed 
an inverse dose-rate effect (Gridley DS 2005; Sgouros et al. 2007) i.e. the observation 
that low-dose-rate (LDR) leads to reduced survival compared to high-dose-rate (HDR). 
Among the different possible explanations for this observation, a lower activation of the 
DNA damage sensor ataxia-telangiectasia mutated (ATM) for cells irradiated at LDR 
compared to HDR was evidenced (Collis et al. 2004). These results suggest that the low 
ATM activation and the resulting lower rate of phosphorilated histone H2AX (γ-H2AX) 
led to a lower cell survival, possibly due to an ineffective activation of cell cycle 
checkpoint and repair mechanisms.   
The results obtained in this work are of potential interest when the response of normal 
tissues is considered: the range of beta particles of 1.75 MeV in lung tissues is about 8 
mm. For 250 keV X-rays, only 11% are absorbed within this distance. X-rays will thus 
depose most of their energy in the surrounding tissues up to 17 cm from the tumor. The 
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use of a beta emitter for lung tumor treatment should allow normal tissues to be spared, 
as non-targeted irradiation can be avoided due to the radiation range.   
Further studies are warranted to confirm the potential of using LDR beta particles for 
tumor sterilization while sparing normal tissues.   
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Figure 1: A549 cell surviving fraction 8 days after beta irradiation from 32P (0.8 Gy/h). 
The experimental data were obtained with conventional colony forming assays.  
A: Surviving fraction curve performed with dose ranging from 0.125 to 10 Gy. LQ 
model (dashed line) and IndRep model (straight line) were applied to experimental data 
(filled square). Results are expressed as means  standard deviation.  The inset is an 
enlargement of the data obtained at low doses. 
B: Experimental data (filled square), LQ model (dashed line) and IndRep model 
(straight line) linearization.   
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Figure 2: A549 cell surviving fraction 8 days after X-ray irradiation (0.855 Gy/min). The 
experimental data were obtained with conventional colony forming assays.  
A: Surviving fraction curve performed with dose ranging from 0.125 to 10 Gy. LQ model 
(dashed line) and IndRep model (straight line) were applied to experimental data (open 
triangle). Results are expressed as means  standard deviation. The inset is an enlargement of 
the data obtained at low doses. 
B: Experimental data (filled circle), LQ model (dashed line) and IndRep model (straight line) 
linearization. 
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Figure 3: Comparison of 32P experimental data (filled square), X-ray irradiation 
experimental data (open triangle), IndRep model for 32P (straight line) and IndRep 
model for X-rays (dashed line). Results are expressed as means  standard deviation.  
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Table I: Parameters obtained from the LQ and IndRep model fit of the survival fraction 
of A549 cells. Survival fractions were obtained with conventional clonogenic assays 
performed 8 days after 
32
P beta irradiation (0.8 Gy/h) or X-irradiation (0.855 Gy/min). 
Parameters and uncertainties were obtained from chi-square minimization fitting 
method of the experimental data.  
 
 r (Gy
-1
)  (Gy-2) s (Gy
-1
) Dc (Gy) r/(Gy) D (Gy) SF2 
32
P 0.21±0.02 0.019±0.002  2.1±1.2 0.27±0.10 11±2.1 3.2 0.61 
X-rays 0.14±0.02 0.038±0.003 1.8±1.2 0.20±0.12 3.7±0.8 3.3 0.65 
 
